
Dr. Shitara on Analyzing the Effects of Prior Therapy on TAS-102 in Gastric/GEJ Cancer
Kohei Shitara, MD, discusses the rationale to analyze the effects of prior therapy on outcomes with TAS-102 in patients with metastatic gastric/gastroesophageal junction cancer.
Kohei Shitara, MD, chief, Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, discusses the rationale to analyze the effects of prior therapy on outcomes with TAS-102 (trifluridine/tipiracil; Lonsurf) in patients with metastatic gastric/gastroesophageal junction (GEJ) cancer.
During the
TAS-102 is an oral combination that was approved in February 2019 for the treatment of patients with metastatic gastric/GEJ cancer who have received at least 2 prior lines of chemotherapy based on data from the TAGS trial. The regimen is also approved in the European Union and Japan for use in this patient population, concludes Shitara.



































